Table 2.
Summary of tumor response and survival outcome.
| HER2-low (N = 144) | HER2-positive (N = 173) | Overall (N = 317) | |
|---|---|---|---|
| ORR | 35 (24.3%) | 77 (44.5%) | 112 (35.3%) |
| CBR | 63 (43.8%) | 115 (66.5%) | 178 (56.2%) |
| DCR | 108 (75.0%) | 150 (86.7%) | 258 (81.4%) |
| Primary resistance | 35 (24.3%) | 22 (12.7%) | 57 (18.0%) |
| rwPFS (months) | 5.6(4.2-7.0) | 10.5 (8.0-12.6) | 7.6(6.7-9.2) |
| rwOS (months) | 18.5(14.6-NA) | 29.9 (25.9-NA) | 28.4(21.1-NA) |
Abbreviations: CBR, clinical benefit rate; DCR, disease control rate; HER2, human epidermal growth factor receptor 2; ORR, objective response rate; rwOS, real-world overall survival; rwPFS, real-world progression-free survival